Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence

Inclusion Criteria: Cohort 1: Oncology patients * Age \>18 years * Histological diagnosis of endometrial hyperplasia with and without atypia, endometrial carcinoma endometrioid histotype at any stage of the disease (FIGO I-IV), patients subjected to hysterectomy for benign extra-endometrial pathology, patients with recurrence/metastasis from endometrioid endometrial carcinoma who undergo surgery; * Adequate biological material to be able to carry out the planned analyses; * Written informed consent (only for patients in the prospective part and/or in follow up/traceable); * For the retrospective part: availability of samples adequately stored at the biobank of the Institute and availability of data relating to follow-up (at least 36 months). Cohort 2: Patients with ongoing spontaneous abortion * Age \>18 years; * Diagnosis of ongoing spontaneous abortion which is subjected to an instrumental review procedure of the uterine cavity, under hysteroscopic guidance; * Adequate biological material to be able to carry out the analyzes previously described; * Written informed consent. Exclusion Criteria: * Comorbidities not controlled with adequate medical therapy; * Infections of the endometrial cavity (pyometra); * Synchronous tumors; * Neoadjuvant treatments; * Previous radiation treatments on the pelvic region.